Examining diabetic nephropathy through the lens of mouse genetics

Current Diabetes Reports

Volumn 7, Issue 6, 2007, Pages 459-466

  Breyer, Matthew D ^a   Tchekneva, Elena ^b   Qi, Zhonghua ^b   Takahashi, Takamune ^b   Fogo, Agnes B ^b   Harris, Raymond C ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; BRADYKININ RECEPTOR; CALGRANULIN; CD134 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN CDC42; PROTEIN S 100; RAC1 PROTEIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

129 MOUSE; ANIMAL MODEL; BAGG ALBINO MOUSE; C57BL 6 MOUSE; DBA 2 MOUSE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; FOCAL GLOMERULOSCLEROSIS; GENE EXPRESSION; GENE LOCUS; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; GLOMERULOSCLEROSIS; HEREDITY; HOMOZYGOTE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INBRED STRAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY FAILURE; KIDNEY FIBROSIS; KNOCKOUT MOUSE; MOUSE; MUTAGENESIS; NEPHROSCLEROSIS; NONHUMAN; PATHOGENESIS; QUANTITATIVE TRAIT LOCUS MAPPING; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STRAIN DIFFERENCE; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE;

ANIMALS; DIABETIC NEPHROPATHIES; MICE; MICE, INBRED STRAINS; MUTAGENESIS; QUANTITATIVE TRAIT LOCI;

EID: 37349091490     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0078-3     Document Type: Review

References (68)

1. Parving HH: Initiation and progression of diabetic nephropathy. N Engl J Med 1996, 335:1682-1683.
2. US Renal Data System: Excerpts from the USRDS 2005 annual data report. Am J Kidney Dis 2005, 47:S1-S286.
3. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group [no authors listed]. N Engl J Med 2000, 342:381-389.
4. Krolewski M, Eggers PW, Warram JH: Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int 1996, 50:2041-2046.
5. Knowler WC, Coresh J, Elston RC, et al.: The Family Investigation of Nephropathy and Diabetes (FIND): design and methods. J Diabetes Complications 2005, 19:1-9.
6. Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989, 320:1161-1165.
7. Iyengar SK, Abboud HE, Goddard KAB, et al.: Genome-wide scans for diabetic nephropathy and albuminuria in multi-ethnic populations: the Family Investigation of Nephropathy and Diabetes. Diabetes 2007, 56:1577-1585.
8. Chavers BM, Bilous RW, Ellis EN, et al.: Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med 1989, 320:966-970.
9. Breyer MD, Bottinger E, Brosius FC 3rd, et al.: Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005, 16:27-45.
10. Beck JA, Lloyd S, Hafezparast M, et al.: Genealogies of mouse inbred strains. Nat Genet 2000, 24:23-25.
11. Wade CM, Daly MJ: Genetic variation in laboratory mice. Nat Genet 2005, 37:1175-1180.
12. Yang H, Bell TA, Churchill GA, Pardo-Manuel de Villena F: On the subspecific origin of the laboratory mouse. Nat Genet 2007, 39:1100-1107.
13. Gurley SB, Clare SE, Snow KP, et al.: Impact of genetic background on nephropathy in diabetic mice. Am J Physiol Renal Physiol 2006, 290:214-222.
14. Qi Z, Fujita H, Jin J, et al.: Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005, 54:2628-2637.
15. Ma LJ, Fogo AB: Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int 2003, 64:350-355.
16. Qi Z, Whitt I, Mehta A, et al.: Serial determination of glomerular filtration rate in conscious mice using FITC-insulin clearance. Am J Physiol Renal Physiol 2004, 286: F590-F596.
17. Mathews CE, Langley SH, Leiter EH: New mouse model to study islet transplantation in insulin-dependent diabetes mellitus. Transplantation 2002, 73:1333-1336.
18. Festing MF, Simpson EM, Davisson MT, Mobraaten LE: Revised nomenclature for strain 129 mice. Mamm Genome 1999, 10:836.
19. Hartner A, Cordasic N, Klanke B, et al.: Strain differences in the development of hypertension and glomerular lesions induced by deoxycorticosterone acetate salt in mice. Nephrol Dial Transplant 2003, 18:1999-2004.
20. Susztak K, Bottinger E, Novetsky A, et al.: Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 2004, 53:784-794.
21. Park CW, Kim HW, Ko SH, et al.: Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor (alpha). Diabetes 2006, 55:885-893.
22. Sharma K, McCue P, Dunn SR: Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003, 284:1138-1144.
23. Naggert JK, Mu JL, Frankel W, et al.: Genomic analysis of the C57BL/ Ks mouse strain. Mamm Genome 1995, 6:131-133.
24. Pillebout E, Burtin M, Yuan HT, et al.: Proliferation and remodeling of the peritubular microcirculation after nephron reduction: association with the progression of renal lesions. Am J Pathol 2001, 159:547-560.
25. Zheng S, Noonan WT, Metreveti NS, et al.: Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 2004, 53:3248-3257.
26. Zheng Z, Schmidt-Ott KM, Chua S, et al.: A Mendelian locus on chromosome 16 determines susceptibility to doxorubicin nepbropathy in the mouse. Proc Natl Acad Sci U S A 2005, 102:2502-2507.
27. Kimura M, Takahasi H, Ohtake T, et al.: Interstrain differences in murine daunomycin-induced nephrosis. Nephron 1993, 63:193-198.
28. Tay YC, Wang Y, Kairaitis L, et al.: Can murine diabetic nephropathy be separated from superimposed acute renal failure? Kidney Int 2005, 68:391-398.
29. Ikeda H: KK mouse. Diabetes Res Clin Pract 1994, 24: S313-S316.
30. Shike T, Gohda T, Tanimoto M, et al.: Chromosomal mapping of a quantitative trait locus for the development of albuminuria in diabetic KK/Ta mice. Nephrol Dial Transplant 2005, 20:879-885.
31. Zanchi A, Moczulski DK, Hanna LS, et al.: Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 2000, 57:405-413.
32. Shin Shin Y, Back SH, Chang KY, et al.: Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy. Diabetes Res Clin Pract 2004, 65:257-265.
33. Zhao HJ, Wang S, Cheng H, et at.: Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006, 17:2664-2669.
34. Kanetsuna Y, Takahashi K, Nagata M, et al.: Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am J Pathol 2007, 170:1473-1484.
35. Nakagawa T, Sato W, Glushakova O, et al.: Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007, 18:539-550.
36. Frye EB, Degenhardt TP, Thorpe SR, Baynes JW: Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J Biol Chem 1998, 273:18714-18719.
37. Cohen MP: Intervention strategies to prevent pathogenetic effects of glycated albumin. Arch Biochem Biophys 2003, 419:25-30.
38. Vlassara H, Brownlee M, Cerami A: Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Nat Acad Sci U S A 1981, 78:5190-5192.
39. Wendt T, Tanji N, Guo J, et al.: Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003, 14:1383-1395.
40. Hofmann MA, Drury S, Fu C, et al.: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/ calgranulin polypeptides. Cell 1999, 97:889-901.
41. Lander HM, Tauras JM, Ogiste JS, et al.: Activation of the receptor for advanced glycation end products triggers a p21 (ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997, 272:17810-17814.
42. Wendt TM, Tanji N, Guo J, et al.: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123-1137.
43. Inagi R, Yamamoto Y, Nangaku M, et al.: A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes 2006, 55:356-366.
44. Yamamoto Y, Kato I, Doi T, et al.: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001, 108:261-268.
45. Dunn SR, Qi Z, Bottinger EP, et al.: Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 2004, 65:1959-1967.
46. Yuen PS, Dunn SR, Miyaji T, et al.: A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol Renal Physiol 2004, 286:1116-1119.
47. Kakoki M, Takahashi N, Jennette JC, Smithies O: Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Nat Acad Sci USA 2004, 101:13302-13305.
48. Tan Y, Keum JS, Wang B, et al.: Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol 2007, Jun 27; [Epub ahead of print].
49. Hrabe de Angelis MH, Flaswinkel H, et al.: Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet 2000, 25:444-447.
50. Favor J: Mechanisms of mutation induction in germ cells of the mouse as assessed by the specific locus test. Mutat Res 1999, 428:227-236.
51. Beier DR: Sequence-based analysis of mutagenized mice. Mamm Genome 2000, 11:594-597.
52. Cordes SP: N-ethyl-N-nitrosourea mutagenesis: boarding the mouse mutant express. Microbiol Mol Biol Rev 2005, 69:426-439.
53. Nolan PM, Hugill A, Cox RD: ENU mutagenesis in the mouse: Application to human genetic disease. Brief Funct Genomic Proteomic 2002, 1:278-289.
54. Nadeau JH, Frankel WN: The roads from phenotypic variation to gene discovery: mutagenesis versus QTLs. Nat Genet 2000, 25:381-384.
55. Su LK, Kinzler KW, Vogelstein B, et al.; Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992, 256:668-670.
56. Vitaterna MH, King DP, Chang AM, et al.: Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science 1994, 264:719-725.
57. Imperatore G, Knowler WC, Pettitt DJ, et al.: Segregation analysis of diabetic nephropathy in Pima Indians. Diabetes 2000, 49:1049-1056.
58. Vardarli I, Baier LJ, Hanson RL, et al.: Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int 2002, 62:2176-2183.
59. Tchekvena EE, Rinchik EM, Polosukhina D, et al.: A sensitized screen of ENU mutagenized mice identifies dominant mutants predisposed to diabetic nephropathy. J Am Soc Nephrol 2007, 18:103-112.
60. Flint J, Valdar W, Shifman S, Mott R: Strategies for mapping and cloning quantitative trait genes in rodents. Nat Rev Genet 2005, 6:271-286.
61. Stoll M, Kwitek-Black AE, Cowley AW Jr, et al.: New target regions for human hypertension via comparative genomics. Genome Res 2000, 10:473-482.
62. Sugiyama F, Churchill GA, Higgins DC, et al.: Concordance of murine quantitative trait loci for salt-induced hypertension with rat and human loci. Genomics 2001, 71:70-77.
63. Korstanje R, DiPetrillo K: Unraveling the genetics of chronic kidney disease using animal models. Am J Physiol Renal Physiol 2004, 287:347-352.
64. Vitt U, Gietzen D, Stevens K, et al.: Identification of candidate disease genes by EST alignments, synteny, and expression and verification of Ensembl genes on rat chromosome 1q43-54. Genome Res 2004, 14:640-650.
65. Clee SM, Yandell BS, Schueler KM, et al.: Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. Nat Genet 2006, 38:688-693.
66. Klein RF, Allard J, Avnur Z, et al.: Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 2004, 303:229-232.
67. Wang X, Ria M, Ketmenson PM, et al.: Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 2005, 37:365-372.
68. Peirce JL, Lu L, Gu J, et al.: A new set of BXD recombinant inbred lines from advanced intercross populations in mice. BMC Genet 2004, 5:7.